TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06075511

Intervention type: DIAGNOSTIC_TEST
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal testing
Description: Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life
Description: Subject will complete Quality of Life Questionnaire
Study: NCT06159582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSTEP
Description: eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual HIV testing and PrEP clinical care
Study: NCT05740982

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
Study: NCT06456268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibraCool mechanical stimulation and neuromodulatory therapeutic device
Description: Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryocompression (Game Ready, Bregs) device
Description: Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ice packs
Description: Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
Study: NCT05666713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELLTALE BASILICA procedure
Description: The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
Study: NCT05913349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Description: Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Description: Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
Study: NCT04985903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Communication Intervention
Description: The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5A's lecture
Description: a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
Study: NCT05955261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
Study: NCT04985903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A's lecture
Description: a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
Study: NCT06659029

Intervention type: DRUG
Intervention: Anifrolumab
Description: Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
Study: NCT06599632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-based Cognitive Behavioral Therapy (V-CBT)
Description: The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
Study: NCT04874155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System - Active
Description: Noninvasive peripheral nerve stimulation device programmed to active mode.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NTX100 Neuromodulation System - Sham
Description: Noninvasive peripheral nerve stimulation device programmed to sham mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System - Open-Label
Description: Noninvasive peripheral nerve stimulation device programmed to active mode.
Study: NCT06674954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study: NCT06205355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia/Nociception Index (ANI) monitoring
Description: intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
Study: NCT05558514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Place-based cochlear implant mapping
Description: Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default cochlear implant mapping
Description: At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
Study: NCT05078008

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy modalities
Description: parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy modalities
Description: parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balneotherapy modalities
Description: Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
Study: NCT05348603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.
Study: NCT05955261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
Study: NCT05348603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.
Study: NCT06310031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrioVAD System
Description: Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate 3
Description: Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
Study: NCT06632470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome injection
Description: Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12 Injection
Description: Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
Study: NCT06633575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
Study: NCT06633432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture stimulation
Description: The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
Study: NCT06696768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study: NCT05460741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated exercise approach
Description: Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: educational program related to menstrual cycle will be given to females.
Study: NCT03955224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basic Oral Care + active LLLT
Description: * Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic oral Care + inactive LLLT
Description: * Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Oral Care
Description: Compliance with the Basic Oral Care only
Study: NCT05844098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-wire
Description: K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.